BACKGROUND: The histopathological structure of malignant tumours involves two essential compartments - the tumour parenchyma with the actual transformed cells, and the supportive tumour stroma. The latter consists of specialized mesenchymal cells, such as fibroblasts, macrophages, lymphocytes and vascular cells, as well as of their secreted products, including components of the extracellular matrix, matrix modifying enzymes and numerous regulatory growth factors and cytokines. In consequence, the tumour stroma has the ability to influence virtually all aspects of tumour development and progression, including therapeutic response. AIM: In this article we review the current knowledge of tumor stroma interactions in urothelial carcinoma and present various experimental systems that are currently in use to unravel the biological basis of these heterotypic cell interactions. RESULTS: For urothelial carcinoma, an extensive tumour stroma is quite typical and markers of activated fibroblasts correlate significantly with clinical parameters of advanced disease. Another clinically important variable is provided by the stromal expression of syndecan-1. CONCLUSION: Integration of markers of activated stroma into clinical risk evaluation could aid to better stratification of urothelial bladder carcinoma patients. Elucidation of biological mechanisms underlying tumour-stroma interactions could provide new therapeutical targets.
BACKGROUND: The histopathological structure of malignant tumours involves two essential compartments - the tumour parenchyma with the actual transformed cells, and the supportive tumour stroma. The latter consists of specialized mesenchymal cells, such as fibroblasts, macrophages, lymphocytes and vascular cells, as well as of their secreted products, including components of the extracellular matrix, matrix modifying enzymes and numerous regulatory growth factors and cytokines. In consequence, the tumour stroma has the ability to influence virtually all aspects of tumour development and progression, including therapeutic response. AIM: In this article we review the current knowledge of tumor stroma interactions in urothelial carcinoma and present various experimental systems that are currently in use to unravel the biological basis of these heterotypic cell interactions. RESULTS: For urothelial carcinoma, an extensive tumour stroma is quite typical and markers of activated fibroblasts correlate significantly with clinical parameters of advanced disease. Another clinically important variable is provided by the stromal expression of syndecan-1. CONCLUSION: Integration of markers of activated stroma into clinical risk evaluation could aid to better stratification of urothelial bladder carcinomapatients. Elucidation of biological mechanisms underlying tumour-stroma interactions could provide new therapeutical targets.
Authors: D Mennerich; A Vogel; I Klaman; E Dahl; R B Lichtner; A Rosenthal; H-D Pohlenz; K-H Thierauch; A Sommer Journal: Eur J Cancer Date: 2004-06 Impact factor: 9.162
Authors: Robert E Hurst; Paul J Hauser; Kimberly D Kyker; Jonathan E Heinlen; Jason P Hodde; Michael C Hiles; Stanley D Kosanke; Mikhail Dozmorov; Michael A Ihnat Journal: PLoS One Date: 2013-05-24 Impact factor: 3.240
Authors: Howard Y Chang; Julie B Sneddon; Ash A Alizadeh; Ruchira Sood; Rob B West; Kelli Montgomery; Jen-Tsan Chi; Matt van de Rijn; David Botstein; Patrick O Brown Journal: PLoS Biol Date: 2004-01-13 Impact factor: 8.029
Authors: Henry M Smilowitz; Lauren J Tarmu; Mary Melinda Sanders; John A Taylor; Dharamainder Choudhary; Crystal Xue; Nathaniel A Dyment; Dan Sasso; Xiaomeng Deng; James F Hainfeld Journal: Int J Nanomedicine Date: 2017-10-27
Authors: E Novruzov; K Dendl; H Ndlovu; P L Choyke; M Dabir; M Beu; F Novruzov; E Mehdi; F Guliyev; S A Koerber; I Lawal; G Niegisch; J Debus; U Haberkorn; M Sathekge; F L Giesel Journal: Mol Imaging Biol Date: 2022-03-29 Impact factor: 3.484